Remedy Robotics secures $62M to move its stroke robot toward clinical trials
Remedy Robotics raised $62M in a DCVC-led Series B to push its N1 neurovascular robot toward a University of California trial and possible FDA approval.

Remedy Robotics has closed a $62 million Series B round to take its N1 System, a robot for blood-vessel procedures, closer to clinical trials and a possible FDA approval. DCVC led the round. New backers UC Investments, Skip Capital and Hostplus joined, along with existing investors Build Collective, Blackbird, Divergent Capital and KdT Ventures.
The money will pay for a pivotal trial with the University of California, prototype N1 units placed with clinical partners, and more work on autonomous features. N1 uses machine learning to study scans before a procedure, simulate routes and line up 3D and 2D images in real time. It can run a whole procedure on site, remotely or autonomously, though full autonomy is still in development. The company says it is not approved for sale or clinical use anywhere.
In October 2025, Remedy reported what it called the first remote neurointerventional procedures with N1. It works with more than 100 hospitals and plans partnerships with SVIN Mission Thrombectomy and the Australian Stroke Alliance.
Why it matters
Remedy cites research showing only 2.8% of eligible stroke patients worldwide can get endovascular treatment, so remote operation could widen access to time-critical care. Still unclear are the trial start date, its size and the timing of any regulatory filing. Those details will show how close N1 is to real patients.